As part of our theme of celebrating positives in pharma and health during this difficult and turbulent time, while ensuring that we keep readers abreast of all the key developments amid the pandemic, PharmaTimes has ‘met’ with some of the next generation of leaders who are helping to secure a bright future for their companies and sectors. More on this on page 24.
Elsewhere, our cover feature (p15) looks at how pharma is rising to the challenge of ensuring a continuous supply of medicines in the wake of Brexit and the coronavirus pandemic, while Sebastian Johnson details how researchers at Oxfordshire’s unique life sciences ecosystem are leading the response to COVID-19 (p36).
Also on coronavirus, the team at Wilmington consider how it is shifting elements of the NHS Long Term Plan, outlining both the positives and negatives (p18), and we look at how the virus has hit the care of non-COVID-19 patients and the potential impact of this on death rates and economies (p7 and p42).
Finally, a reminder that the PharmaTimes Marketer of the Year, Communications Awards and Sales Awards are open for entry (visit www.pharmatimes.com/competitions for more information), while there’s also still time to enter the inaugural Patient Partnership Index (www.patientpartnershipindex.com), which closes for entry on June 23.
PharmaTimes and OVID Health have launched the first ever Patient Partnership Index. We talk to judges Jill Pearcy, director of ABPI Code Engagement at the Association of the British Pharmaceutical Industry, and Richard Davidson, chief executive of Sarcoma UK, about the importance of initiative and its potential impact
As the NHS battles to suppress the coronavirus, communities across Britain have been adjusting to a new reality. Meanwhile, pharma has taken on the task of managing, sustaining and boosting its international supply chains. The industry is, so far, rising to the challenge, creating a new template and a revised plan for the future
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the Long Term Plan while putting others in jeopardy
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
PharmaTimes talks to some of pharma and healthcare’s most promising young leaders, already making waves in their companies and brightening the future
Ben Osborn, Pfizer’s UK country manager, shares his thoughts on why the Patient Partnership Index and the values it celebrates matter more now than ever before....
Is pharma ready for the effects of the climate crisis on global health?
The doctor will see you (online) now, but so could the fraudsters
Andrew Rut on why drug safety should be top of mind during COVID-19 development
Oxfordshire has a unique life sciences ecosystem which has enabled it to mobilise rapidly and lead the international response to COVID-19, says Sebastian Johnson
Remote treatment calls for a collaborative approach
While the NHS has focused on fighting coronavirus, care for non-COVID patients has dropped sharply. Will those patients come back?
